Last updated July 18, 2026
Key finding
Data entries decreased significantly from the first quarter to the second quarter (p = 0.001).
The Telemechron study will evaluate the impact of a digital platform on diabetes management among individuals with type 2 diabetes and non-ideal glycaemic values.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The Telemechron study will evaluate the impact of a digital platform on diabetes management among individuals with type 2 diabetes and non-ideal glycaemic values.
Understanding the effectiveness of technology-based interventions in diabetes management could provide valuable insights for healthcare providers. If successful, such interventions may improve patient engagement and health outcomes, ultimately reducing complications associated with diabetes.
The effectiveness of the interventions remains unclear based on current data. The study may have limitations in generalizability due to specific population characteristics. Potential confounding factors may not be fully accounted for in the analysis.
Published in
Publication details and source links for this paper.
Alexia G, Lorenzo G, Maria AG, et al. Organizational models supported by technology for the management of diabetic disease and its complications in a diabetic clinical setting: study protocol for a randomized controlled trial targeting type 2 diabetes individuals with non-ideal glycaemic values (Telemechron study). Frontiers in Clinical Diabetes and Healthcare. 2025;6:1589548. doi:10.3389/fcdhc.2025.1589548
HbA1c levels will be assessed at 12 months with no significant change expected between groups.
App usage data entries will show a significant decrease from the first to the second quarter (p = 0.001).
The System Usability Scale (SUS) score will indicate high satisfaction with the platform, with a median score of 95.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to TreC Diabete digital platform and Decrease in app usage data entries, HbA1c, System Usability Scale (SUS) score.
This study contributes evidence to
Primary intervention
TreC Diabete digital platform
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
3
Evidence pairs
310
Related studies
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
TreC Diabete digital platform → Decrease in app usage data entries
TreC Diabete digital platform → Decrease in app usage data entries
TreC Diabete digital platform → System Usability Scale (SUS) score
TreC Diabete digital platform → System Usability Scale (SUS) score
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Digital Storytelling Interventions and Decrease in app usage data entries, Digital Storytelling Interventions and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Behavioral & Lifestyle
Behavioral & Lifestyle
Curated evidence collections and hubs this study is part of.
All studies measuring Decrease in app usage data entries
Measures Decrease in app usage data entries as a key outcome.
All studies on Digital Storytelling Interventions
Contributes to Digital Storytelling Interventions evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Digital Storytelling Interventions may improve HbA1c.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Current evidence does not show a clear benefit of Digital Storytelling Interventions for Digital Usability and Experience.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
System Usability Scale (SUS) score
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
TreC Diabete digital platform appears to improve Decrease in app usage data entries.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Decrease in app usage data entries
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
